Title:
HUMANIZED ANTIBODIES AGAINST OX40, METHOD FOR PREPARING THE SAME, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/119792
Kind Code:
A1
Abstract:
Provided in the present disclosure are humanized antibodies against tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as OX40 and CD134. It also provides the methods of hybridoma generation, the nucleic acid molecules encoding the anti-OX40 antibodies, expression vectors and host cells used for the expression of anti-OX40 antibodies. The disclosure further provides the methods for validating the function of antibodies in vitro and the efficacy of antibodies in vivo. The antibodies of the disclosure provide a very potent agent for the treatment of multiple cancers vial modulating human immune function.
Inventors:
ZHENG YONG (CN)
YANG BAOTIAN (CN)
LI JING (CN)
YANG BAOTIAN (CN)
LI JING (CN)
Application Number:
PCT/CN2019/125244
Publication Date:
June 18, 2020
Filing Date:
December 13, 2019
Export Citation:
Assignee:
WUXI BIOLOGICS SHANGHAI CO LTD (CN)
WUXI BIOLOGICS IRELAND LTD (IE)
WUXI BIOLOGICS IRELAND LTD (IE)
International Classes:
C07K16/28; A61K39/395; A61P37/02; C12N15/13
Foreign References:
| CN108822213A | 2018-11-16 |
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF: